Company intelligence / Profile preview

BioMed X

Heidelberg, Baden-Württemberg, Germany

Ownership: Private
Employees: ~81
Development stage: Other

Overview

BioMed X has run 26 projects sponsored by 12 global pharma partners, yielding >60 publications and numerous young scientist careers; outcomes include preclinical asset development and transfer to pharma partner pipelines

Therapeutic areas: OncologyNeurologyImmunology
Modalities: Small moleculeAntibodyBiologicRNA therapyArtificial intelligence platform
Industry: Drug Discovery Services

Partnerships

AstraZenecaMerckPfizerTevaIsrael Biotech FundAmiti VenturesAmazon Web Services (AWS)Israel Innovation Authority (IIA)Other global pharma sponsors

Beyond the preview

Go deeper on BioMed X.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioMed X.

Explore the full profile